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Summary 
High-density hpoprotein  (HDL) has been found to neutralize LPS activity in vitro and in ani- 
mals in vivo. We  sought  to  determine  the  effects of reconstituted  HDL  (rHDL)  on LPS re- 
sponsiveness  in humans in  a  double-blind,  randomized,  placebo-controlled,  cross-over study. 
rHDL, given as a 4-h infusion at 40 mg/kg starting 3.5 h  before endotoxin  challenge  (4 ng/kg), 
reduced  flu-like  symptoms  during  endotoxemia,  but  did  not  influence  the  febrile  response. 
rHDL  potently  reduced  the  endotoxin-induced  release  of TNF,  IL-6,  and  IL-8,  while  only 
modestly attenuating the secretion ofproinflammatory cytokine inhibitors  IL-lra, soluble TNF 
receptors  and  IL-10.  In addition,  rHDL attenuated  LPS-induced  changes in leukocyte  counts 
and the  enhanced  expression  of CD11b/CD18  on granulocytes.  Importantly,  rHDL infusion 
per se, before LPS  administration,  was associated with  a  downregulation  of CD14,  the  main 
LPS  receptor,  on  monocytes.  This  effect was  biologically  relevant,  since  monocytes  isolated 
from rHDL-treated  whole  blood  showed  reduced  expression  of CD14  and  diminished  TNF 
production  upon  stimulation  with LPS.  These results suggest that rHDL may inhibit  LPS ef- 
fects in humans in vivo not only by binding and neutralizing  LPS but also by reducing  CD14 
expression on monocytes. 
T 
he systemic toxicity of Gram-negative sepsis is in large 
part mediated by endotoxin  which  induces  an exten- 
sive  inflammatory  response  characterized  by  cytokine  re- 
lease and activation of leukocytes.  Once in the circulation, 
endotoxin  is bound by lipopolysaccharide-binding  protein 
(LBP) 1 which  can transfer LPS to either cell-bound  CD14 
(causing activation of these cells), to soluble CD14 (facihta- 
ring activation ofceUs not expressing CD14 on their surface), 
or to lipoproteins  (1-7). Binding of LPS to lipoproteins re- 
sults in inactivation  of LPS (8-11).  Preincubation  of endo- 
toxin with low-density lipoprotein  (LDL), very-low density 
lipoprotein  (VLDL) and chylomicrons reduced  endotoxin- 
induced lethality (12), whereas hypolipidemic animals were 
more sensitive to endotoxin  (13).  Further,  transgenic  mice 
with elevated apolipoprotein A-1  (apoA-1) and HDL levels 
are protected against LPS-induced  mortality (14). 
The  endotoxin-neutralizing  capacity  of lipoproteins  is 
dependent  on the lipid composition.  Reconstituted  human 
HDL (rHDL), containing purified apoA-1, phosphatidyl cho- 
1Abbreviations used in this paper: apoA-1, apohpoprotein  A-l; HDL, high-den- 
sity hpoprotein; LBP, hpopolysaccharide-binding  protein; LDL, low-density 
lipoprotein; rHDL, reconstituted human HDL; VLDL, very low-density 
lipoprotein. 
line and cholesterol,  neutralized  endotoxin  in whole blood 
more effectively than LDL, VLDL, and natural HDL (15, 16). 
Pretreatment  of animals  with  rHDL reduced  endotoxin- 
induced  TNF  production,  leukopenia  and  lethality  (17- 
19).  The present study was designed  to investigate the  en- 
dotoxin-neutrahzing  properties  of rHDL  (40  mg/kg)  in 
humans in vivo. 
Materials and Methods 
Human Endotoxemia.  Eight  healthy  male  volunteers  (mean 
age 24, range 20-28 yr) were enrolled in this double-blind, cross- 
over,  randomized,  placebo-controlled  study.  Written  informed 
consent was obtained from all participants. Medical history, phys- 
ical and routine laboratory examination, chest x-ray and electro- 
cardiogram were normal. The volunteers did not smoke, did not 
use  any medication  and  did  not  have  any febrile  illness  in  the 
month preceding the study. Each participant was studied on two 
occasions, separated by a wash-out period of six weeks. On one 
occasion the subject was challenged with endotoxin in combina- 
tion with placebo, on the other in combination with rHDL. The 
study was approved by the research and ethical committees of the 
Academic Medical Center. 
The study drug rHDL Lot no. 4.955.006.0  (ZLB Central Lab- 
oratory, Bern,  Switzerland)  was supplied as a pyrogen-free lyo- 
philized product with 91% apoA-1 purity (20).  The appropriate 
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saccharose,  was  aspirated  into  dark-colored  Amberlite  syringes 
(Plastipak,  Becton-Dickinson, Mountain View, CA) and admin- 
istered as a 4-h infusion through an intravenous line at a dose of 
40 mg/kg.  The placebo solution consisted of isotonic saline and 
was administered in an identical manner. 
The Escherichia coli endotoxin preparation used in this study, lot 
EC-6  (D.  Hochstein,  Bureau  of Biologics, Food and  Drug Ad- 
ministration,  Bethesda,  MD)  was  administered  over one minute 
in an antecubital vein of the contralateral arm at a dose of 4 ng/kg, 
3.5  h  after the initiation of the placebo  or rHDL  infusion.  The 
study was performed at a special research unit under continuous 
supervision of at least two physicians with emergency and resusci- 
tation equipment immediately available. Blood pressure and heart 
rate were assessed  every 30  min using a Dinamap  device (Criti- 
con, Tampa,  FL)  during  the first 8  h  after endotoxin  challenge; 
oral  temperature  and  respiratory  rate  were  assessed  at  the  same 
time points. Adverse events were registered throughout the con- 
finement  periods  by  a  clinical  symptom  score.  Adverse  events 
were scored by incidence and severity (0 as absent,  1 as weakly, 
2 as moderately, and 3 as severely present). 
Whole Blood Incubation and In  Vitro PBMC Stimulation.  In  sep- 
arate in vitro experiments, blood was collected into pyrogen-free 
tubes  (Falcon  2063;  13ecton  Dickinson,  Mountain  View,  CA), 
containing  pyrogen-free  heparin  (Thromboliquine®;  Organon, 
Oss, the Netherlands,  final concentration 30 IU/ml). After incu- 
bation of whole blood with rHDL (final concentration 0.5 or 2.0 
mg/ml) for  1 h  in a  5% CO2 incubator  at 37°C,  blood was  di- 
luted  1:1  in PBS and subsequently  human  P13MC  were isolated 
by  centrifugation  over a  Lymphopaque  density  gradient  (Ficoll 
Paque; Pharmacia, Woerden, the Netherlands)  at room tempera- 
ture  for  25  rain  at  1,000  2-  After  three  washes,  P13MC  were 
brought  to a  concentration  of 5  X  106 cells/ml with H13SS and 
CD14  expression on monocytes was measured using FACScan  ® 
analysis  as described below. In parallel experiments, PBMC  (5  X 
106 cells/ml) were  stimulated with  LPS  (E.  coli 0111:134;  Sigma 
Chem. Co., St. Louis, MO; final concentration 10 ng/ml) for 4 h 
at 37°C in H13SS containing 10% sterile non-acute human serum 
(Central Laboratory of the Netherlands  Red Cross Blood Trans- 
fusion Service CLB, Amsterdam, the Netherlands). 
After incubation, samples were centrifuged and stored at -20°C 
until TNF analysis.  All experiments were performed four times. 
Assays.  For leukocyte and differential counts, blood was col- 
lected in tubes containing EDTA (K3) (15%)  and counted by flow 
cytometry (Technicon H1  system,  Technicon Instruments,  Tar- 
rytown, NY). Blood for LPS measurements was collected in py- 
rogen-free plastic tubes (model 2063;  Falcon, Oxnard,  CA) con- 
taining  pyrogen-free  heparin  (final  concentration  30  IU/ml, 
Thromboliquine®; Organon).  For the Limulus assay, platelet rich 
plasma  was  prepared  by  centrifugation  of heparinized  blood  at 
180 g for 10 min at 4°C and subsequently stored at -20°C. The 
Limulus assay was performed as described previously (21).  Inhibi- 
tors and activated clotting factors were removed by dilution and 
heating at 37°C for 5 rain. Standard curves were made with E. coli 
055; B5 (Mallinckrodt Inc., St. Louis, MO). This assay had a de- 
tection limit in plasma of 36 EU/1. Cytokines were determined in 
serum  using  specific ELISAs  (TNF,  IL-6,  IL-8,  IL-10,  soluble 
TNF  receptors  I  and  II  [sTNFr  I  and  II],  and  soluble  CD14 
[sCD14]; Medgenix Diagnostic, Brussels, Belgium; IL-1 receptor 
antagonist [IL-lra]; R&D Systems, Abingdon, United Kingdom). 
L13P was measured in serum using reagents kindly provided by 
Dr.  S.  Carroll  (Xoma  Corporation,  Berkeley,  CA),  as described 
previously (22).  HDL cholesterol concentrations were assayed  us- 
ing  nephelometry  (Boehringer  Mannheim,  Mannheim,  Ger- 
many). 
FACScan ® Analysis.  At  -3.5,  0,  3,  and  24  h  relative  to 
endotoxin  challenge  blood  was  drawn  into  tubes  containing 
15% EDTA (I(3) and placed on ice. After lysis of the erythrocytes 
with isotonic  NH4C1 solution  (155  mmol/1 NH4C1,  10  mmol/1 
KHCO3, 0.1  mmol/1 EDTA, pH 7.4),  samples were centrifuged 
at  300 2  for  10  min  and  residual  erythrocytes  were  lysed for  5 
min. The remaining cells were washed twice in PBS and subse- 
quently fixed in PBS,  containing  1%  BSA,  0.3  mmol/1 EDTA, 
0.01% sodium azide and 0.1% paraformaldehyde  (final concentra- 
tion  5  X  106  cells/ml).  All procedures  were  performed  at  4°C. 
The following antibodies were used:  FITC anti-human  CD11b, 
FITC  anti-human  CD14,  and  FITC  anti-human  CD18  (CLB- 
mon-gran/1,B2,  CL13-mon/1,SG3,  CLB-LFA-1/1,5D7,  respec- 
tively; Central  Laboratory  of the  Netherlands  Red  Cross Blood 
Transfusion  Service CLB,  Amsterdam,  The  Netherlands).  As  a 
control FITC IgG 1 (Becton Dickinson) was used.  Cells were in- 
cubated for 30 min at 4°C after addition of the mAb to the cell 
suspension  and  washed  twice in  ice-cold P13S, containing 0.1% 
BSA, 0.3 mmol/L EDTA, 0.01% sodium azide. The mean fluo- 
rescence intensities (MFI) of labeled granulocytes and monocytes 
were recorded using FACS  ®, after gating the cells using their for- 
ward and side scatter properties.  Per time point 10,000  granulo- 
cytes and 2,500 monocytes were counted.  After subtracting con- 
trol IgG1 fluorescence, specific antibody binding was expressed as 
percent changes from pretreatment  values obtained  at 3.5  h  be- 
fore endotoxin challenge. Antibodies against apoA-1  or rHDL in 
the sera of the volunteers were determined by ELISA before and 
three months after rHDL infusion. Either rHDL or apoA-1 were 
used as coats on microtiter plates,  and were incubated with vol- 
unteer's  serum.  The  assay  developed  with  a  sheep  antiserum 
against  human  apoA-I  and  an  anti-sheep  IgG  alkaline  phos- 
phatase conjugate. Positive controls included tests of the individ- 
ual sera with a tetanus toxoid coat, and a test with rabbit anti-human 
apoA-1  on the apoA-1 coat with the corresponding second anti- 
body. 
Statistical Analysis.  Values are given as mean  +SEM.  Differ- 
ences between placebo  and  rHDL treatment  periods  in the hu- 
man  endotoxemia  model  were  tested  by  analysis  of variance 
(ANOVA)  for  repeated  measures  using  SPSS  for  Windows. 
Changes  of  parameters  in  time  were  tested  using  one-way 
ANOVA. Differences in CD14 expression and TNF production 
in  the  in vitro  experiments  were  analyzed  using  the  Wilcoxon 
test. A two-sided P value <0.05  was considered significant. Inci- 
dence and mean severity of clinical symptoms associated with en- 
dotoxemia  were  tabulated;  summary  results  are  given in  a  de- 
scriptive way. 
Results 
Human  Endotoxemia 
Clinical Symptoms and  Vital Signs.  Endotoxin  administra- 
tion  elicited  clinical  symptoms  similar  to  those  reported 
previously  (23,  24).  Briefly,  flu-like  symptoms  were  ob- 
served including headache,  chills,  nausea,  vomiting,  myal- 
gia and backache.  All volunteers were symptom free within 
24 h  after endotoxin challenge. 
Infusion  of  rHDL  did  not  cause  any  side-effects  or 
changes in routine laboratory parameters.  After rHDL treat- 
ment circulating HDL  cholesterol concentrations  increased 
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Treatment/  Placebo and  rHDL and 
symptoms  endotoxin (n =  8)  endotoxin (n =  8) 
Headache  8 (1.5)  8 (1.1) 
Chills  5 (0.6)  2 (0.4) 
Myalgia  5 (0.9)  3 (0.4) 
Backache  5 (0.6)  1 (0.3) 
Nausea  5 (0.8)  3 (0.3) 
Vomiting  3 (0.8)  0 (0) 
Incidence and mean severity of clinical symptoms in human endotox- 
emia as scored during the time of confinement. The total of volunteers 
suffering from a specific event during placebo/endotoxin treatment and 
rHDL/endotoxin (40 mg/kg) treatment is given, with in parentheses 
the mean severity (0 =  absent,  1 =  mild, 2 =  moderate,  and 3  =  se- 
vere). 
from  1.16  +  0.06  mmol/1 at  t  =  -3.5  h  to  1.64  +  0.07 
mmol/1 at t  =  6 h. HDL levels remained elevated until the 
end of the study period,  1.48  +  0.05  mmol/1 at  t  =  24  h 
(P <0.001  in time). 
During the  3-mo follow up period none of the partici- 
pants developed antibodies against Apo A-1 or rHDL. Fur- 
thermore, no seroconversion in HIV 1/2, hepatitis A, hep- 
atitis B  surface, hepatitis B  core, hepatitis C, and parvovirus 
B19  status was  observed within the  3-mo observation pe- 
riod. 
As is shown in Table  1,  rHDL  reduced  the  endotoxin- 
induced clinical symptoms.  In contrast,  rHDL  did not in- 
fluence the  febrile  response  to  endotoxin.  Peak  tempera- 
tures were 37.8  +-  0.3°C and 37.6  -+  0.3°C after injection 
of endotoxin in conjunction with placebo  and rHDL,  re- 
spectively. 
Endotoxin Activity in Plasma.  Peak endotoxin plasma lev- 
els  were  observed  5  min  after  endotoxin  injection,  rHDL 
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Figure  2.  Mean (-+SEM) circulating concentrations ofTNF (A), IL-6 
(B) and IL-8  (C) after endotoxin administration in humans. Endotoxin 
was given in combination with control (open circles) or rHDL (40 mg/kg, 
closed circles), P value indicates difference between treatment groups. 
sured by the Limulus assay (21.8  +  8.7 pg/ml versus 46.0  -+ 
5.7 pg/ml, P  =  0.001)  (Fig.  1). 
Cytokines.  Endotoxin  administration  resulted  in  tran- 
sient increases in serum levels of TNF  (peak level 4.50  -+ 
1.79 ng/ml at t =  2 h), IL-6 ( peak level 13.79  ___ 5.75 ng/ml 
at t  =  4 h), and IL-8 ( peak level 2.05  -+ 0.50 ng/ml at t  = 
3  h). rHDL treatment importantly reduced the release of all 
three cytokines (P <0.001  versus placebo): TNF  (peak level 
0.52 +  0.11 ng/ml at t =  1.5 h), IL-6 (peak level 1.75  +  0.45 
ng/ml at t  =  2 h), and IL-8 ( peak level 0.75  +  0.25 ng/ml 
at t  =  3 h) (Fig. 2). 
rHDL had a less pronounced inhibiting effect on the re- 
lease  of antagonist cytokines during endotoxemia.  During 
endotoxin/placebo  administration  IL-lra  levels  increased 
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Figure 3.  Mean (-+SEM) circulating concentrations oflL-lra (A), [L-10 (B), sTNFr I (C), and sTNFr II (D) in human endotoxemia.  Endotoxin was 
given in combination  with control (open circles) or rHDL (40 mg/kg, closed circles), P value indicates difference between treatment groups. 
from 0.64 +  0.11 ng/ml (baseline) to 557.75  -+ 68.29 ng/ml 
(t =  3  h); IL-10 to 0.13  +  0.03 ng/ml at t  =  3 h; sTNFr I 
from 1.86  --- 0.12 ng/ml to 5.96  +  0.20 ng/ml at t  =  2  h; 
sTNFr II from 3.52  -4- 0.25 ng/ml to  13.30  _+  0.73 ng/ml 
at  t  =  4  h.  rHDL  infusion modestly decreased  the  endo- 
toxin-induced release oflL-lra  (390.50  -+ 70.42 ng/ml at 
t =  3 h, P  =  0.023); sTNFr I (5.56 --- 0.38 ng/ml at t =  2 h; 
P  =  0.007); sTNFr II (11.92  +  0.94 ng/ml at t  =  3 h; P  = 
0.024).  The rHDL-induced inhibition of IL-10 release did 
not reach statistical significance (Fig. 3). 
Leukocyte Responses.  After  endotoxin  challenge  leuko- 
cyte counts decreased from 4.5  +  0.4  ×  109/1 at  -3.5  h  to 
1.9  +  0.3  ×  109/1 at t  =  1 h  followed by an increase up to 
12.8  +  1.8  ×  109/1  at  t  =  8  h.  rHDL  blunted both  the 
early leukopenia (3.1  +- 0.5  ×  109/1 (t =  1 h) and the sub- 
sequent rise in leukocyte counts (10.8  +  1.2  ×  109/1 at t = 
10 h)  (P <0.001).  Neutrophil counts closely followed total 
leukocyte counts; rHDL attenuated both the initial neutro- 
penia and the subsequent neutrophilia. After endotoxin chal- 
lenge,  the  monocyte  count dropped  from  0.4  -+  0.04  × 
109/1 (baseline) to 0.02  +  0  ×  109/1 (t =  1 h) followed by 
a rise to 1.0 +  0.3  ×  109/1 (t =  24 h). rHDL administration 
reduced  both  endotoxin-induced  monopenia  and  mono- 
cytosis (0.05  -+  0.01  ×  109/1 at t  =  1 h  and 0.5  +  0.07  × 
109/1 at t =  24 h)  (P =  0.01)  (Fig. 4). 
CD11b expression on granulocytes obtained from endo- 
toxin challenged volunteers increased to 401.2  +  116.5% at 
t  =  3  h  (P <0.001  in time) and CD18  to  133.7  ---  13.2% 
(P =  0.004 in time), rHDL treatment significantly reduced 
the endotoxin-induced increase of both CD11b and CD18 
expression  to  168.4  +  45.9%  (CD11b)  and  to  94.8  --- 
13.1%  (CD18)  at  t  =  3  h  (P =  0.02  and P  =  0.04 versus 
placebo, respectively) (Fig. 5). 
Fig.  6  shows  that  endotoxin upregulated CD14  expres- 
sion  on  monocytes  in  vivo,  reaching  a  peak  of 160.2  + 
13.7% at 3 h  after endotoxin challenge (P <0.001  in time). 
Before endotoxin administration, rHDL treatment resulted 
in a  significant reduction  of CD14  expression  on  mono- 
cytes of 71.5  -+  13.7% at t  =  0 h  (P =  0.016 in time); after 
endotoxin  challenge,  CD14  expression  only  increased  to 
106.2  -+  10.6% at 3 h  (P =  0.025 versus placebo). Circulat- 
ing granulocytes exhibited an increase in CD14 expression 
during endotoxin treatment to 343.0  +  25.3% at t  =  24 h 
(P <0.001  in time), and rHDL partially prevented this in- 
crease  (202.3  +  25.2% at  t  =  24 h)  (P <0.001  versus pla- 
cebo). 
Endotoxin-binding  Proteins.  Endotoxin challenge slightly 
decreased  sCD14  concentrations from  2.71  +-  0.07  (g/ml 
at t =  -3.5  h  to 2.43  +  0.24 (g/ml at t =  2 h  (P =  0.02 in 
time), which was not influenced by rHDL (P =  1.0) (Fig. 6). 
LBP levels rose from 2.8  +- 0.2 (g/ml at t =  -3.5  h  to 12  + 
1.9  (g/ml 24 h  after  endotoxin administration, which was 
reduced by rHDL  (9.9  -+  1.1  (g/ml at t  =  24 h; P  =  0.03 
versus placebo)  (Fig. 7). 
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Figure  5.  Mean (+SEM) relative mean fluorescence intensity (MFI) of 
CD11b  (A) and CD18  (B) on circulating granulocytes in human endo- 
toxemia. Control saline (open circles) or rHDL (40 mg/kg, closed circles) was 
given as a 4-h infusion in combination with endotoxin (4 ng/kg), P value 
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Figure 4.  Mean  (-+SEM) leukocyte counts and differential counts in 
human endotoxemia. Endotoxin was given in combination with control 
saline (open circles) or rHDL (40 mg/kg, closed dr&s). Leukocyte (A),  gran- 
ulocytes (B), monocytes (C), P value indicates difference between treat- 
ment groups. 
In  Vitro  Whole  Blood  Incubation  and PBMC  Stimulation 
After incubation of whole blood with 0.5 mg/ml rHDL, 
a dose corresponding to the in vivo concentrations achieved 
in this study, CD14  expression on monocytes was reduced 
to  72.5  -+  1.0%  (P <0.001).  The  reduction of CD14  ex- 
pression on monocytes was even greater after incubation of 
whole blood with 2.0 mg/rnl rHDL (36.0 -+ 0.3%, P <0.001) 
(Fig.  8  A).  PBMC  isolated  from  rHDL-treated  whole 
blood  did  not  produce  detectable  TNF  levels  spontane- 
ously. As shown in Fig. 8 B, a dose-dependent reduction in 
TNF production by endotoxin-stimulated PBMC  (isolated 
from rHDL-treated whole blood) was seen from 3.9  -+ 0.2 
ng/ml  (control, no rHDL added) to 2.5  +  0.2 ng/ml  (0.5 
mg/ml  rHDL)  and  1.4  +-  0.3  ng/ml  (2.0  mg/ml  rHDL) 
(P =  0.01  for each). 
Discussion 
The  present  study  is  the  first to  demonstrate  the  LPS- 
neutralizing capacity of rHDL  in humans  in vivo.  rHDL, 
given as an  intravenous  infusion starting before induction 
of endotoxemia  in  healthy  volunteers,  markedly reduced 
TNF, IL-6, and IL-8, while only modestly reducing the re- 
lease  of the  proinflammatory  cytokine  inhibitors,  IL-lra, 
sTNFr I, sTNFr II, and  IL-10.  Further,  rHDL  attenuated 
endotoxin-induced  clinical symptoms  and  leukocyte acti- 
vation. These LPS-inhibiting effects appeared in part to be 
mediated  by  a  rHDL-induced  downregnlation  of mono- 
cyte-bound CD14,  the predominant receptor for LPS. 
During the rHDL treatment period, endotoxin levels, as 
measured  with  the  LAL  assay,  were  significantly higher 
than  during  the  endotoxin/placebo  treatment  period and 
endotoxin  remained  detectable  in  the  circulation  longer. 
These findings are in accordance with  a previous study in 
which  patients  with  high  HDL  levels exhibited a  higher 
LPS recovery upon ex vivo stimulation with LPS in com- 
parison with patients with low HDL levels (25).  It should 
be noted that the LAL assay includes a dilution and heating 
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Figure 6.  Mean (±SEM) relative mean fluorescence  intensity (MFI) of 
CD14  on  circulating  monocytes  (A)  and  neutrophils  (t3) and  mean 
(±SEM) concentrations of soluble CD14 in human endotoxemia, rHDL 
(40 mg/kg, dosed circles) treatment was compared with control saline (open 
circles), P value indicates difference between treatment groups. 
step  in  which  endotoxin  is  recovered  from  LPS-binding 
proteins such as LBP and presumably also from HDL.  The 
increased  LAL  activity  after  rHDL/endotoxin  treatment 
merely  indicates  that  rHDL  indeed  bound  LPS  in  vivo. 
Thus,  LAL activities do  not necessarily represent bioactive 
endotoxin levels in humans in vivo. 
The  reduction  in  the  release  of proinflammatory  cyto- 
kines  by  rHDL  was  larger  than  the  reduction  in  IL-lra, 
15 
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Figure 7.  Mean (±SEM) concentrations of LBP after endotoxin chal- 
lenge in humans. Open circles represent the endotoxin/placebo treatment 
period,  closed  circles represent endotoxin/rHDL (40  mg/kg) treatment 
period. 
sTNF  receptors,  and IL-10.  Thus, the potency with which 
rHDL  influenced various LPS responses differed.  Conceiv- 
ably,  part  of the  LPS  administered  did  not  associate  with 
rHDL.  In this context, the threshold dose at which LPS in- 
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Figure 8.  Effect  of rHDL  on monocyte CD14  expression  and TNF 
production. Whole blood was incubated with rHDL (0, 0.5, or 2.0 mg/ml) 
for 1 h at 37°C.  Thereafter, PBMC were isolated and CD14 expression 
on  monocytes was  determined by  FACScan  ® (A), or  isolated  PBMC 
were stimulated with LPS for 4 h and TNF production was assessed (B). 
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of proinflammatory cytokines and leukocyte activation. 
In this study we demonstrate for the first time that CD14 
expression  on monocytes was  increased  in vivo after LPS 
administration.  Previous in vitro studies showed that LPS is 
able to increase CD14 expression on monocytes (26), while 
others  found  that  LPS  decreased  CD14  expression  (27). 
However, clear evidence is given that blocking CD 14 on both 
monocytes and neutrophils attenuated LPS responses (4, 28). 
An  important  and  new  finding  is  that  rHDL  induced  a 
downmodulation  of CD14 at the  surface  of monocytes in 
vivo and  in whole  blood  in  vitro.  We  demonstrated  that 
this reduction in CD14 expression may be biologically rel- 
evant,  since monocytes isolated from rHDL-treated whole 
blood produced less TNF upon stimulation with LPS. The 
mechanism by which rHDL downregulates monocyte CD14 
expression  remains  to  be  elucidated.  If CD14  was  shed 
from the  monocyte cell  surface by rHDL,  one  might  ex- 
pect  an  elevation  in  sCD14  levels.  In  our  study  sCD14 
concentrations  did  not  increase  during  rHDL  treatment, 
but  a small  change in sCD14 levels by rHDL might have 
been masked by the already high concentrations of sCD14 
constitutively present  in  the  circulation.  Nonetheless,  our 
data  suggest  that  it  is  conceivable  that  rHDL may reduce 
endotoxin-induced  TNF  production  not only by binding 
and  neutralizing  endotoxin,  but  also  by  reducing  CD14 
monocyte surface expression. 
A previous in vitro study demonstrated that activation of 
granulocyte [32 integrin (CD11b/CD18)  on PMN occurred 
by binding of LPS-LBP complexes on CD14 on PMN and 
could be blocked by anti-CD14 antibodies  (4).Thus the re- 
duction  of CD11b/CD18  expression  on  neutrophils  by 
rHDL  in  our  study  might  be  caused  directly  by reduced 
presentation  of LPS-LBP complexes.  It seems unlikely that 
the  reduction  in  CDllb/CD18  is  caused  by  rHDL- 
induced  attenuation  in  CD14  expression  on  granulocytes 
because the reduction of LPS-induced increase of CD11b/ 
CD18  expression  by rHDL preceded  the  rHDL-induced 
reduction of CD14 expression on granulocytes. As [3"2  inte- 
grins participate in the adhesion ofneutrophils to endothe- 
lium,  the  reduction  in  [32 integrin  expression  may prevent 
endotoxin-associated endothelial damage (29, 30). 
In  conclusion,  the  results  of this  study  clearly  demon- 
strate  that  rHDL,  given  as  a  4-h infusion  at  a  dose  of 40 
mg/kg,  dramatically  reduced  the  endotoxin-induced  in- 
flammatory response as measured by reduced inflammatory 
cytokines, cell activation, and clinical symptoms in humans. 
This  is  partly  caused  by  neutralization  of endotoxin  by 
rHDL and by rHDL-induced  reduction  in  CD14  expres- 
sion on monocytes. 
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